Proteomic analysis of Class IV lupus nephritis

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 62-70

  Alaiya, Ayodele ^a   Assad, Lina ^a   Alkhafaji, Dania ^a   Shinwari, Zakia ^a   Almana, Hadeel ^a   Shoukri, Mohamed ^a   Alkorbi, Lutfi ^a   Ibrahim, Hossamaldin Galal ^a   Abdelsalam, Mohamed Said ^a,b   Skolnik, Edward ^c   Adra, Chaker ^a,d   Albaqumi, Mamdouh ^a,c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

global segmental; lupus nephritis; profiles; proteinexpression; proteomics; renal biopsies

Indexed keywords

14 3 3 PROTEIN EPSILON; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKERATIN 18; CYTOKERATIN 19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZRIN P81; GLUTATHIONE PEROXIDASE 3; LIPOCORTIN 5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN; RITUXIMAB; SEROTRANSFERIN; SERUM ALBUMIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PROTEOME;

ADULT; ALOPECIA; ANCA ASSOCIATED VASCULITIS; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; LIQUID CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POST HOC ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; RECURRENCE RISK; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; CLASSIFICATION; FOLLOW UP; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS NEPHRITIS; MALE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEOME; PROTEOMICS; RECURRENCE; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84922469732     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu215     Document Type: Article

References (34)

1. Appel GB, Cohen DJ, Pirani CL et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885
2. Markowitz GS, DAgati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71: 491-495
3. Weening JJ, DAgati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
4. Hill GS, Delahousse M, Nochy D et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68: 2288-2297
5. Yokoyama H, Wada T, Hara A et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66: 2382-2388
6. Mittal B, Hurwitz S, Rennke H et al. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004; 44: 1050-1059
7. Gbadegesin R, Bartkowiak B, Lavin PJ et al. Exclusion of homozygous PLCE1 (NPHS3) mutations in 69 families with idiopathic and hereditary FSGS. Pediatr Nephrol 2009; 24: 281-285
8. Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol 2003; 23: 141-146
9. Fogo AB. The spectrum of FSGS: does pathology matter? Nephrol Dial Transplant 2010; 25: 1034-1036
10. Alaiya AA, Franzen B, Moberger B et al. Two-dimensional gel analysis of protein expression in ovarian tumors shows a low degree of intratumoral heterogeneity. Electrophoresis 1999; 20: 1039-1046
11. Franzen B, Auer G, Alaiya AA et al. Assessment of homogeneity in polypeptide expression in breast carcinomas shows widely variable expression in highly malignant tumors. Int J Cancer 1996; 69: 408-414
12. Alaiya A, Fox J, Bobis S et al. Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate. Cancer Genomics Proteomics 2014; 11: 39-49
13. Barr RG, Seliger S, Appel GB et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18: 2039-2046
14. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006; 70: 1403-1412
15. Lewis EJ, Schwartz MM, Korbet SM. Severe lupus nephritis: importance of re-evaluating the histologic classification and the approach to patient care. J Nephrol 2001; 14: 223-227
16. Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-A UK-wide study. Am J Surg Pathol 2006; 30: 1030-1035
17. Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005; 4: 1213-1222
18. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 2003; 3: 9-15
19. Hanash S. Disease proteomics. Nature 2003; 422: 226-232
20. Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002; 1: 117-124
21. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001; 19: 515-523
22. Bendtzen K, Buschard K, Diamant M et al. Possible role of IL-1, TNFalpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Thyroid Cell Group. Lymphokine Res 1989; 8: 335-340
23. Brereton CF, Sutton CE, Lalor SJ et al. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol 2009; 183: 1715-1723
24. Hur W, Cho ML, Yoon SK et al. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. Immunol Lett 2006; 106: 154-162
25. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Stills disease and systemic- onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008; 17: 349-359
26. Botsios C, Sfriso P, Furlan A et al. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis. Reumatismo 2007; 59: 32-37
27. Takemura T, Yoshioka K, Murakami K et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994; 424: 459-464
28. Boswell JM, Yui MA, Burt DW et al. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141: 3050-3054
29. Kiberd BA, Stadnyk AW. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology 1995; 30: 131-137
30. Schorlemmer HU, Kanzy EJ, Langner KD et al. Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity on BDF1 hybrid mice and MRL autoimmune mice. Agents Actions 1993; 39 Spec. No: C117-120
31. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163
32. Alaiya A, Roblick U, Egevad L et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000; 21: 1-9
33. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997; 18: 533-537
34. Izzotti A, Bagnasco M, Cartiglia C et al. Proteomic analysis as related to transcriptome data in the lung of chromium(VI)-treated rats. Int J Oncol 2004; 24: 1513-1522